Barrows Stephanie M, Wright Kelly, Copley-Merriman Catherine, Kaye James A, Chioda Marc, Wiltshire Robin, Torgersen Knut Martin, Masters Elizabeth T
Market Access and Outcomes Strategy, RTI Health Solutions, Ann Arbor, MI, USA,
Epidemiology and Clinical Research, RTI Health Solutions, Waltham, MA, USA.
Lung Cancer (Auckl). 2019 Feb 8;10:11-20. doi: 10.2147/LCTT.S179349. eCollection 2019.
The objective of this study was to understand outcomes of patients treated with ALK inhibitors, especially when ALK inhibitors are followed by other ALK inhibitors. A systematic literature review was conducted in PubMed, Embase, and Cochrane through July 17, 2017. Conference abstracts (three meetings in past 2 years) also were searched. Of 504 unique publications, 80 met inclusion criteria (47 clinical trials, 33 observational studies). Observational studies have the potential to provide information for ALK inhibitors used sequentially. Ten observational studies reported median overall survival of crizotinib-led sequences ranging from 30.3 to 63.75 months from initiation of crizotinib; 49.4-89.6 months from metastatic non-small-cell lung cancer diagnosis; and 15.5-22.0 months from initiation of the second-generation ALK inhibitor after initial crizotinib. Sequencing of ALK inhibitors may benefit patients progressing on initial ALK inhibitors.
本研究的目的是了解接受ALK抑制剂治疗的患者的预后情况，尤其是在ALK抑制剂之后再使用其他ALK抑制剂时的情况。截至2017年7月17日，我们在PubMed、Embase和Cochrane数据库中进行了系统的文献综述。我们还检索了会议摘要（过去两年内的三次会议）。在504篇独立发表的文献中，有80篇符合纳入标准（47项临床试验，33项观察性研究）。观察性研究有可能为序贯使用ALK抑制剂提供信息。十项观察性研究报告了以克唑替尼为首的治疗序列的中位总生存期，从克唑替尼开始使用起为30.3至63.75个月；从转移性非小细胞肺癌诊断起为49.4至89.6个月；从初始克唑替尼后开始使用第二代ALK抑制剂起为15.5至22.0个月。ALK抑制剂的序贯使用可能使初始ALK抑制剂治疗后病情进展的患者受益。
